Please be advised that the site will be down for maintenance on Sunday, September 1, 2024, from 08:00 to 18:00, and again on Monday, September 2, 2024, from 08:00 to 09:00. We apologize for any inconvenience this may cause.
dc.contributor.author | Matshe, William M.R.![]() |
|
dc.contributor.author | Tshweu, Lesego L.![]() |
|
dc.contributor.author | Mvango, Sindisiwe![]() |
|
dc.contributor.author | Cele, Zamani E.D.![]() |
|
dc.contributor.author | Chetty, Avashnee S.![]() |
|
dc.contributor.author | Pilcher, Lynne A.![]() |
|
dc.contributor.author | Famuyide, Ibukun Michael![]() |
|
dc.contributor.author | McGaw, Lyndy Joy![]() |
|
dc.contributor.author | Taylor, Dale![]() |
|
dc.contributor.author | Gibhard, Liezl![]() |
|
dc.contributor.author | Basarab, Gregory S.![]() |
|
dc.contributor.author | Balogun, Mohammed O.![]() |
|
dc.date.accessioned | 2024-08-22T10:34:22Z | |
dc.date.available | 2024-08-22T10:34:22Z | |
dc.date.issued | 2023-05 | |
dc.description | DATA AVAILABILITY STATEMENT : The data that support the findings of this study are available from the corresponding author upon reasonable request. | en_US |
dc.description.abstract | Uncomplicated malaria is effectively treated with oral artemisinin-based combination therapy (ACT). Yet, there is an unmet clinical need for the intravenous treatment of the more fatal severe malaria. There is no combination intravenous therapy for uncomplicated due to the nonavailability of a water-soluble partner drug for the artemisinin, artesunate. The currently available treatment is a two-part regimen split into an intravenous artesunate followed by the conventional oral ACT . In a novel application of polymer therapeutics, the aqueous insoluble antimalarial lumefantrine is conjugated to a carrier polymer to create a new water-soluble chemical entity suitable for intravenous administration in a clinically relevant formulation . The conjugate is characterized by spectroscopic and analytical techniques, and the aqueous solubility of lumefantrine is determined to have increased by three orders of magnitude. Pharmacokinetic studies in mice indicate that there is a significant plasma release of lumefantrine and production its metabolite desbutyl-lumefantrine (area under the curve of metabolite is ≈10% that of the parent). In a Plasmodium falciparum malaria mouse model, parasitemia clearance is 50% higher than that of reference unconjugated lumefantrine. The polymer-lumefantrine shows potential for entering the clinic to meet the need for a one-course combination treatment for severe malaria. | en_US |
dc.description.department | Chemistry | en_US |
dc.description.department | Paraclinical Sciences | en_US |
dc.description.librarian | am2024 | en_US |
dc.description.sdg | SDG-03:Good heatlh and well-being | en_US |
dc.description.sponsorship | World Health Organization; South African Medical Research Council; National Research Foundation of South Africa. | en_US |
dc.description.uri | http:// www.mbs-journal.de | en_US |
dc.identifier.citation | Matshe, W.M.R., Tshweu, L.L., Mvango, S. et al. 2023, 'A water-soluble polymer-lumefantrine conjugate for the intravenous treatment of severe malaria', Macromolecular Bioscience, vol. 23, art. 2200518, pp. 1-12. DOI: 10.1002/mabi.202200518. | en_US |
dc.identifier.issn | 1616-5187 (print) | |
dc.identifier.issn | 1616-5195 (online) | |
dc.identifier.other | 10.1002/mabi.202200518 | |
dc.identifier.uri | http://hdl.handle.net/2263/97813 | |
dc.language.iso | en | en_US |
dc.publisher | Wiley | en_US |
dc.rights | © 2023 The Authors. Macromolecular Bioscience published by Wiley-VCH GmbH. This is an open access article under the terms of the Creative Commons Attribution License. | en_US |
dc.subject | Drug delivery | en_US |
dc.subject | Infectious disease | en_US |
dc.subject | Lumefantrine | en_US |
dc.subject | Nanomedicine | en_US |
dc.subject | Polymer therapeutics | en_US |
dc.subject | Severe malaria | en_US |
dc.subject | Artemisinin-based combination therapy (ACT) | en_US |
dc.subject | Malaria | en_US |
dc.subject | SDG-03: Good health and well-being | en_US |
dc.title | A water-soluble polymer-lumefantrine conjugate for the intravenous treatment of severe malaria | en_US |
dc.type | Article | en_US |